Heart failure is a clinical syndrome due to a structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood in order to deliver oxygen at a rate commensurate with the requirements of the metabolizing tissues.
Symptoms are caused by ventricular dysfunction secondary to abnormalities of the myocardium, pericardium, endocardium, valves, heart rhythm and conduction.
Chronic heart failure is a state where patient's signs and symptoms have been unchanged (stable) for at least a month but may decompensate suddenly or slowly when stable chronic heart failure deteriorates leading to hospitalization.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
In patients with heart failure with preserved ejection fraction (HFpEF), angiotensin-neprilysin inhibition with sacubitril/valsartan confers better renoprotection than valsartan alone, reducing the risk of adverse renal events and the speed of decline in estimated glomerular filtration rate (eGFR), a study has found.
Patients with heart failure with reduced ejection fraction (HFrEF) who achieve 100 percent guideline-recommended target dose (GRTD) for both angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) and β-blockers have a reduced risk of all-cause mortality and heart failure hospitalization (HHF), a recent study showed.
While the clinical risk factors for atrial fibrillation (AF) and its associated adverse outcomes are similar across ethnicities in Asia, AF is more common in some ethnic groups than the others, reveal the latest data from the ASIAN-HF* registry.
Patients with type 2 diabetes mellitus (T2DM) who are overweight or obese but have high cardiorespiratory fitness (CRF)* may have a reduced risk of heart failure (HF), according to a study presented at EPI Lifestyle 2020.
A novel, wearable heart failure (HF) patch accurately predicted worsening HF and impending rehospitalization days before the event actually happened in adults who were recently discharged from hospitalization for HF (HHF), according to the LINK-HF* study.
Routine use of cardiac magnetic resonance (CMR) imaging is not superior to a selective use strategy in terms of refining the clinical categorization of heart failure (HF) aetiology in patients with nonischaemic HF, a study reports. However, CMR improves the detection of specific HF diagnoses compared with echocardiography (ECG), and specific HF aetiologies are associated with poor outcomes.
Left ventricular assist devices (LVADs) improve survival and quality of life (QoL) in patients with advanced heart failure (HF). At the National Heart Centre Singapore (NHCS), a mechanical cardiac support (MCS) programme in place since 2001 has shown a 2-year survival rate of 100 percent with the use of continuous flow pumps.
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.